SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the conferen ...

SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the first patient enrolled in the Phase III randomized procedure placebo-controlled double-blind CardiAMP HF II clinical trial of the Company’s lead autologous cell therapy program for the treatment of heart failure at BayCare Morton Plant Hospital in Clearwater, Florida. “We are excited to le ...

Independent Data Safety Monitoring Board (DSMB) recommends that the study proceeds as designed based on 30-day data safety assessment of participants treated in low dosage group. The company plans to progress the trial to enrollment of 39 participants in the United States. SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the study's in ...

CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress Dr. Arshed Quyyumi, Professor of Medicine, Division of Cardiology, Department of Medicine, Emory University School of Medicine, and Co-Director of the Emory Clinical Cardiovascular Research Institute to Serve as Principal Investigator SUNNYVALE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global ...

BioCardia (BCDA) Q4 2024 Earnings Call April 01, 2025 02:50 AM ET Company Participants Miranda Fido - Investor RelationPeter Altman - President & Chief Executive OfficerDavid McClung - Chief Financial OfficerJoe Pantginis - Managing Director Conference Call Participants Kumaraguru Raja - Senior Biotechnology AnalystJames Molloy - Managing Director, Senior Biotechnology & Specialty Pharmaceuticals Equity Analyst Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioC ...

BioCardia, Inc. (BCDA) Q4 2024 Earnings Conference Call March 31, 2025 04:30 PM ET Company Participants Conference Operator - ModeratorMiranda Vito - BioCardia and Vesta Relations RepresentativeDr. Peter Altman - President and CEO, BioCardiaDavid McClung - Chief Financial Officer, BioCardiaKumar Raja - Investor, Brookline Capital Markets Conference Call Participants Joe Pangenese - Analyst, HC WainwrightJames F. Malloy - Analyst, Alliance Global Partners Conference Operator Ladies and gentlemen, thank you f ...

A webcast replay of the call will be available approximately one hour after the end of the call at the above links. To access the replay internationally, please use the link https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic), 1- 412-317-0088 (international) or 855-669-9658 (Canada) by using access code 6220156. Media Contact: Miranda Peto, Marketing / Investor Relations Email: mpeto@BioCardia.com Pho ...

SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT. Participants can register for the conference by navigating to htt ...

Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significance Statistically significant improvement in composite outcome measure comprised of survival, MACCE, and quality of life seen in patients suffering from active heart stress (those with elevated NTproBNP and BNP biomarkers) treated with CardiAMP Cell Therapy Patient improvements through two years suggest single dose of Cardi ...

Financial Performance - Net cash used in operations was approximately $8.0 million in 2024, a decrease from approximately $10.0 million in 2023[9] - Revenues for 2024 were approximately $58,000, down from approximately $477,000 in 2023, primarily due to the fulfillment of performance obligations[9] - Research and development expenses decreased to approximately $4.4 million in 2024 from approximately $7.7 million in 2023, reflecting reduced clinical expenses[9] - Selling, general and administrative expenses decreased to approximately $3.7 million in 2024 from approximately $4.4 million in 2023, due to personnel realignment and cost reductions[9] - The net loss for 2024 was approximately $7.9 million, compared to approximately $11.6 million in 2023[9] - Cash and cash equivalents at the end of 2024 totaled $2.4 million, an increase from $1.1 million at the end of 2023[17] Clinical Trials and Developments - The CardiAMP HF Trial's last protocol-specified follow-up visit has been completed, with data analysis nearing completion for presentation at the American College of Cardiology Scientific Sessions[5] - The first commercial Morph DNA steerable introducer devices have been manufactured and are now available for use in clinical trials and procedures[6] - The company anticipates finalizing the initial trial manuscript for publication and accelerating enrollment activities in the CardiAMP HF II Trial in the coming weeks[5] - The company is preparing for a consultation with Japan's PMDA regarding the registration of the CardiAMP Cell Therapy System for heart failure treatment[5]